Neurocrine Biosciences | NBIX - Ebit


Neurocrine Biosciences reported $239.3M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
AbbVie USD 5.72B 69M Jun/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -116.87M 10.19M Sep/2025
ALKERMES USD 89.08M 3.9M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 34.85M Sep/2025
Amgen USD 4.43B 2.17B Sep/2025
Biogen USD 659.6M 157M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Dynavax Technologies USD 21.27M 10.41M Sep/2025
Exelixis USD 256.36M 42.78M Sep/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 304.96M Sep/2025
Neurocrine Biosciences USD 239.3M 93.7M Sep/2025
Pfizer USD 4.57B 1.97B Sep/2025
Prothena USD -39.76M 12.25M Sep/2025
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Repligen USD 16.81M 10.85M Sep/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Teva Pharmaceutical Industries USD 577M 491M Dec/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025